EUCTR2005-001169-32-IT进行中（未招募）不适用
A randomized two-arm, multicenter, open-label phase III study of BMS-354825 administered orally at a dose of 70 mg twice daily or 140 mg once daily in subjects with chronic myeloid leukemia in accelerated phase or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec). Revised protocol 06, incorporating administrative letters 01, 02, and 03 and amendments 01, 02, 03, 04 (v1.0 dated 28 Feb 2008) and 05 (v1.0 dated 19 Dec 2008).
BRISTOL-M.SQUIBB0 个研究点目标入组 540 人开始时间: 2005年8月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 540
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Pharmacokinetics, pharmacodynamics and safety of DEB025/alisporivir in combination with ribavirin therapy in chronic hepatitis C genotype 2 and 3 patients who have previously failed interferon therapy or are intolerant or unable to take interferoChronic hepatitis CMedDRA version: 18.0Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-003751-38-FRovartis Pharma Services AG52
进行中（未招募）
不适用
A randomized, open-label, 2-arm, multicentre, Phase II study to evaluate the safety and efficacy of Trivax, a dendritic cell-based interleukin-12 secreting autologous cancer vaccine, in combination with Sunitinib compared with Sunitinib alone as first line treatment for patients with metastatic renal-cell carcinoma (mRCC). - Decavarec Study TRX 1.0EUCTR2007-002556-41-CZTrimed Biotech GmbH70
进行中（未招募）
不适用
A randomized, open-label, 2-arm, multicentre, Phase II study to evaluate the safety and efficacy of Trivax, a dendritic cell-based interleukin-12 secreting autologous cancer vaccine, in combination with Sunitinib compared with Sunitinib alone as first line treatment for patients with metastatic renal-cell carcinoma (mRCC). - Decavarec Study TRX 1.0Metastatic renal cell carcinomaMedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaEUCTR2007-002556-41-ATTrimed Biotech GmbH70
进行中（未招募）
不适用
A study to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab/docetaxel in patients with breast cancer that spread to other tissues.First-line treatment of patients with HER2 negative metastatic breast cancer.MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2006-001365-42-ATF. Hoffmann-La Roche Ltd424
进行中（未招募）
不适用
A study to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab/docetaxel in patients with breast cancer that spread to other tissues.First-line treatment of patients with HER2 negative metastatic breast cancer.MedDRA version: 17.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2006-001365-42-GBF. Hoffmann-La Roche Ltd424